Assessment of Sirolimus-Eluting Coronary Stent Implantation With Aspirin Plus Low Dose Ticlopidine Administration One Year Results From CYPHER Stent Japan Post-Marketing Surveillance Registry (J-PMS)
Open Access
- 1 January 2009
- journal article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 73 (6), 1038-1044
- https://doi.org/10.1253/circj.cj-08-0732
Abstract
Background: Clinical data of sirolimus-eluting stent (SES) implantation are under investigation in Japan. Methods and Results: The CYPHER stent Japan Post-Marketing Surveillance Registry (J-PMS) was conducted at 50 medical centers to assess the results of SES in daily clinical practice exclusively under aspirin plus low dose ticlopidine (200 mg/day). A total of 2,459 lesions in 2,054 patients were treated with 3,285 SES. The mean age was 67.1 ±10.1 years, 75.6% were men and 43.3% were diabetics. Intravascular ultrasound was used in 77.2%. The 8-month angiographic and 1-year clinical follow-up data were available in 85.4% and 96.8%, respectively. Quantitative coronary angiography showed the reference vessel diameter and percentage diameter stenosis at baseline were 2.47 ±0.58 mm and 72.0 ±16.1%. The 8-month late loss was 0.20 ±0.50 mm. The major adverse cardiovascular events at 1 year was 7.3%; cardiac death: 1.1%, myocardial infarction (MI): 1.2%, and target lesion revascularization (TLR): 4.2%. The rates of definite and probable stent thrombosis at 1 year were 0.30% and 0.10%, respectively. Hemodialysis was the strongest predictor of death/MI or TLR. Conclusions: J-PMS showed the effectiveness of SES implantation under aspirin plus low dose ticlopidine administration at 1 year, although further studies are necessary to demonstrate the safety. (Circ J 2009; 73: 1038-1044)Keywords
This publication has 42 references indexed in Scilit:
- Sirolimus-Eluting Stents at Two Years: A Pooled Analysis of SIRIUS, E-SIRIUS, and C-SIRIUS With Emphasis on Late Revascularizations and Stent ThrombosesThe American Journal of Cardiology, 2006
- Safety of Coronary Sirolimus-Eluting Stents in Daily Clinical PracticeCirculation, 2006
- Risk of Thrombosis With the Use of Sirolimus-Eluting Stents for Percutaneous Coronary Intervention (from Registry and Clinical Trial Data)The American Journal of Cardiology, 2005
- The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS)Journal of the American College of Cardiology, 2004
- Analysis of 1-Year Clinical Outcomes in the SIRIUS TrialCirculation, 2004
- Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”Circulation, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryThe New England Journal of Medicine, 2003
- Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS)The Lancet, 2003
- A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary RevascularizationThe New England Journal of Medicine, 2002
- Clopidogrel versus ticlopidine after intracoronary stent placementJournal of the American College of Cardiology, 1999